Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | CTSV | O60911 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSH | P09668 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4630708 | 0.81 | GRM5 (0.46) | GRM5NR3C1NR3C2 | |
| SCHEMBL10460756 | 0.69 | KDM4E (0.43) | — | |
| SCHEMBL2172650 | 0.66 | POLB (0.42) | — | |
| SCHEMBL981075 | 0.64 | L3MBTL1 (0.33) | — | |
| SCHEMBL27757872 | 0.62 | HSP90AA1 (0.31) | — | |
| SCHEMBL12830382 | 0.62 | MAPK10 (0.39) | — | |
| SCHEMBL5043858 | 0.60 | PDE10A (0.31) | — | |
| SCHEMBL21877560 | 0.58 | IDH1 (0.35) | — | |
| SCHEMBL25384433 | 0.57 | PTGS2 (0.39) | NR3C1 | |
| SCHEMBL22507480 | 0.56 | HTT (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2550273-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2013-01-30 | — | — | EP | disclosed |
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | GRM5 2789/4885STIM1 1320/4885ORAI1 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.